Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?

The Lancet. Respiratory medicine - 1 Oct 2023

Menis Jessica, Remon Jordi

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37244264
DOI: 10.1016/S2213-2600(23)00216-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?PMID 37244264Read ↗

Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.Semantic proximity Read ↗

Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profileSemantic proximity Read ↗

Dacomitinib: another option for EGFR-mutant lung cancer?Semantic proximity Read ↗

Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?Semantic proximity Read ↗

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read ↗

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studySemantic proximity Read ↗

Befotertinib: First Approval.Semantic proximity Read ↗

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?Semantic proximity Read ↗

Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to ErlotinibSemantic proximity Read ↗

LUX-Lung: determining the best EGFR inhibitor in NSCLC?Semantic proximity Read ↗

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.Semantic proximity Read ↗

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.